drugset / Trial / NCT04143451

Intradermal Influenza Vaccine With Topical Imiquimod in Elderly and Chronic Illness Patients

NCT04143451

Phase 3 Unknown 4000 enrolled The University of Hong Kong
RandomizedCrossoverDouble-blindPrevention

Summary

To compare the safety and clinical efficacy (death, overall hospitalization, hospitalization for influenza or pneumonia) of ID QIV delivered via an intradermal device with imiquimod cream pretreatment with conventional intramuscular (IM) standard dose QIV and IM high-dose TIV

Timeline

Start
2019-10-23
Primary completion
2022-09-30
Completion
2023-03-31

Drugs

EvaluationDrugModalityDoseRoute
Comparator Imiquimod Other / unclassified 5 % Topical
Comparator Imiquimod Other / unclassified 250 mg Topical
Comparator Influenza Virus Vaccine Vaccine 60 ug Intramuscular
Comparator NITRAMINE Vaccine 15 ug Intramuscular

Indications